Dual Diomarkers Triggered Prodrugs for Precise Treatment of Melanoma: Design, Synthesis and Activities

• Published in: Chemical research in Chinese universities 2022-08, Vol.38 (4), p.949-956
• Main Authors: Ruan, Yawen, Huang, Peiling, Yan, Jiangyu, Li, Guorui, Huang, Jing
• Format: Article
• Language: English
• Subjects: Analytical Chemistry; Biomarkers; Chemistry; Chemistry and Materials Science; Chemistry/Food Science; Drugs; Inorganic Chemistry; Melanoma; Mitochondria; Mitochondrial DNA; Organic Chemistry; Physical Chemistry; Selectivity; Toxicity; Tyrosinase
• ISSN: 1005-9040; 2210-3171
• DOI: 10.1007/s40242-022-2121-y

Targeted prodrug strategy, which utilizes the endogenous biomarkers in cancer cells as activators to release the active drug, has been well established either in the fundamental research or the clinical treatment. However, many prodrugs suffer from safety concern due to “off-target activation”. Dual or multiple biomarkers triggered prodrug may provide an effective strategy to overcoming the “off-target effect”. Melanoma cells have both high levels of reactive oxygen species(ROS) and tyrosinase(TYR), which makes them significantly different from other tumor cells and normal cells. Here we reported a series of quinazolinone-aryl boronic acid/ester-based prodrugs, which can be activated by the cascade of ROS and TYR and selectively kill melanoma cells. The structure-activity relationship(SAR) analysis revealed that mitochondria-targeting property was vital for their cytotoxicity and the dual activated effector played a significant role in their selectivity towards melanoma cells. Among these candidates, compound 4 b showed the highest toxicity to B16, leading to an imbalance of the redox system in melanoma cells, causing mitochondrial DNA damage, and then promoting melanoma cells death.